Tiba Biotech LLC
Tuesday, June 04, 2024
Company Presentation
Immunology
Company Presentation Theater 1
Tiba is a pre-clinical stage company founded in 2018 based on 5 years of research on RNA delivery at MIT’s Whitehead and Koch Institutes. We develop RNA vaccines and therapeutics based on a novel nanoparticle technology that can package large nucleic acid payloads with lower inflammatory side effects than current lipid nanoparticle (LNP) technologies. Our proprietary ‘RNABL’ platform is based on a class of biodegradable dendrimer molecules that form highly dense and stable nanoparticles that avoid unwanted uptake in the liver, enabling therapeutic applications in a wider variety of target tissues. With a large library of proprietary RNABL molecules, Tiba scientists can tune RNA delivery to different tissues and cells to suit a particular application. Because RNABL nanoparticles induce lower inflammation than LNPs, Tiba can develop safer medicines with less dose-limiting side effects. In addition to venture funding, we have secured support from the NIH, CEPI, and most recently BARDA.
Company Website:
http://www.tiba.bio
Lead Product in Development:
Avian pandemic influenza vaccine
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Three additional therapeutic programs, beyond government-funded vaccine programs.
Company HQ City
Cambridge
Company HQ State
MA
Company HQ Country
United States
CEO/Top Company Official
Karl Ruping
Development Phase of Primary Product
Pre-Clinical
Primary Speaker